Please use this identifier to cite or link to this item:
Title: Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors
Authors: Francini, Cinzia Maria
Artusi, Roberto
Mennuni, Laura
Calgani, Alessia
Angelucci, Adriano
Schenone, Silvia
Botta, Maurizio 
Keywords: Src kinase; aminoimidazoles; aminothiazoles; antitumor agents; inhibitors
Issue Date: 2015
Project: None 
Src family kinases (SFKs) are a family of non-receptor tyrosine kinases (TKs) implicated in the regulation of many cellular processes. The aberrant activity of these TKs has been associated with the growth and progression of cancer. In particular, c-Src is overexpressed or hyperactivated in a variety of solid tumors and is most likely a strong promoting factor for the development of metastasis. Herein, the synthesis of new 4-aminoimidazole and 2-aminothiazole derivatives and their in vitro biological evaluation are described for their potential use as SFK inhibitors. Initially, 2-aminothiazole analogues of dasatinib and 4-aminoimidazole derivatives were synthesized and tested against the SFKs Src, Fyn, Lyn, and Yes. Five hits were identified as the most promising compounds, with Ki values in the range of 90-480 nM. A combination of molecular docking, homology modeling, and molecular dynamics were then used to investigate the possible binding mode of such compounds within the ATP binding site of the SFKs. Finally, the antiproliferative activities of the best candidates were evaluated against SH-SY5Y and K562 cell lines. Compound 3 b [2-(4-2-methyl-6-[(5-phenylthiazol-2-yl)amino]pyrimidin-4-ylpiperazin-1-yl)ethanol] was found to be the most active inhibitor.
ISSN: 1860-7179
DOI: 10.1002/cmdc.201500428
Appears in Collections:Publications

Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.